menu
    • menu
    [{"orgOrder":0,"company":"Inhibitor Therapeutics","sponsor":"Inhibitor Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibitor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inhibitor Therapeutics \/ Inhibitor Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Inhibitor Therapeutics \/ Inhibitor Therapeutics"},{"orgOrder":0,"company":"Inhibitor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Itraconazole","moa":"||Cytochrome P450 51","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibitor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibitor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inhibitor Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Inhibitor Therapeutics

    Menu

    Inhibitor Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Inhibitor Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Inhibitor Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Itraconazole

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Johns Hopkins University

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University

                            Details : Under the agreement, Inhibitor Therapeutics licenses U.S Patent for New Angiogenesis Inhibitors from JHU, for use of SUBA-Cap (itraconazole) in Prostate Cancer, Basal Cell Carcinoma including Basal Cell Carcinoma Nevus Syndrome (an orphan oncology diseas...

                            Product Name : SUBA-Cap

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 13, 2023

                            Lead Product(s) : Itraconazole

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Johns Hopkins University

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Inhibitor Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Inhibitor Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Itraconazole,Docetaxel,Prednisone

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            INHIBITOR Therapeutics Receives prostate cancer IND Clearance from FDA

                            Details : Phase 2b clinical trial will evaluate the efficacy and safety of SUBA-Itraconazole capsules dosed in combination with docetaxel and prednisone in patients with metastatic castrate resistant prostate cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 22, 2020

                            Lead Product(s) : Itraconazole,Docetaxel,Prednisone

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth